肿瘤标志物联合检测对良性恶性胸腔积液鉴别诊断的临床价值  

Clinical value of combined detection of tumor markers in differentiation of benign and malignant pleural effusion

作　　者：侯卫科[1] 孙云霞[1] 

机构地区：[1]河南宏力医院检验科,长垣453400

出　　处：《中国实用医刊》2011年第23期52-53,共2页Chinese Journal of Practical Medicine

摘　　要：目的探讨胸腔积液中多项肿瘤标志物的联合检测对鉴别良、恶性胸腔积液的临床价值。方法采用贝克曼库尔特ACCESS2全自动化学发光仪测定80例癌性胸腔积液和102例炎性胸腔积液中的癌胚抗原（CEA）、糖类抗原（CAl25）、铁蛋白（SF）三种肿瘤标志物含量，进行对比分析。结果恶性胸腔积液组中CEA、CAl25、SF三种肿瘤标志物平均水平明显高于正常值高限，良性胸腔积液组平均水平低于正常值（P〈0．05），恶性胸腔积液组肿瘤标志物阳性率为96．00％，良性胸腔积液组为26．48％（P〈0．05）。结论胸腔积液CEA、CAl25、SF三种肿瘤标志物联合检测对鉴别良、恶性胸腔积液有临床价值。Objective To study the clinical value of combined detection of tumor markers in differentiate cancer pleural effusion from inflammatory pleural effusion. Methods Eighty cases of cancer pleural effusion and 102 cases of inflammatory pleural effusion were analyzed of the CEA, CA125, SF. Re- sults CEA, CA125, SF levels of cancer pleural effusion group were significantly higher than that of normal average high limit, inflammatory pleural effusion group were below the normal average level （ P 〈 0.05） ; The positive rate of tumor markers in cancer pleurai effusion group was 96.00%, inflammatory hydrothorax group was 26.48% （ P 〈 0. 05）. Conclusions Combined detection of three tumor markers （CEA ,CA125, SF） for differentiation of benign and malignant pleural effusion have clinical value.

关 键 词：肿瘤标志物 胸腔积液 联合检测 

分 类 号：R730.4[医药卫生—肿瘤]